Dr. Timothy A. Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. He is the Ransom Horne, Jr. Endowed Professor for Cancer Research and serves as Vice President and Head of Clinical Development in the Therapeutics Discovery Division, a drug discovery biopharmaceutical division where drug discovery and clinical translation are seamlessly integrated. He is also a Professor in the Department for Investigational Cancer Therapeutics (Phase I Program) and in the Department of Thoracic/Head and Neck Medical Oncology.
Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics, such as ATR, PARP1, WEE1, POLQ, USP1, PKMYT1, PARG, CHK1, ATM and DNA-PK inhibitors, next generation CDK2, CDK4 and CDK7-selective inhibitors, YAP/TEAD inhibitors, Werner helicase inhibitors, SMARCA2 degraders, as well as the development of novel immunotherapeutics.